期刊文献+

Gd-BOPTA增强MRI对小肝癌的诊断价值 被引量:12

Evaluation of Gd-BOPTA Enhanced MRI in the Diagnosis of Small HCC
下载PDF
导出
摘要 目的 比较Gd BOPTA增强MRI与MRI平扫、Gd DTPA动态增强MRI在诊断小肝癌 (SHCC)方面的差异 ,进一步提高小肝癌检出率和诊断准确性并观察其不良反应。资料与方法 手术或穿刺病理证实为SHCC患者 2 5例。采用GESigna 1.5T磁共振扫描仪。行SE序列T1WI、FSE序列T2 WI及Gd DTPA快速动态增强多期扫描。Gd BOPTA增强扫描亦采用静脉团注快速动态增强扫描 (同Gd DTPA) ,并在团注后 15min、6 0min行SE序列T1WI和FMPSPGR序列T1WI扫描各 1次。观察MRI平扫、Gd DTPA快速动态增强和Gd BOPTA增强扫描及延迟扫描对病灶的检出率、包膜显示情况以及病灶的强化特征并行统计学分析。观察其不良反应。结果  2 5例患者共发现病灶4 2个。对SHCC病灶的检出率 ,MRI平扫为 6 9.0 5 % ,Gd DTPA增强为 85 .71% ,Gd BOPTA增强 (动态 +延迟 )为95 .2 4 % ,和Gd DTPA增强之间无统计学差异 ,和MRI平扫有统计学意义。病理检查发现 30个病灶有包膜。Gd BOPTA增强对SHCC包膜的显示 (86 .6 7% )明显优于平扫MRI(2 6 .6 7% )和Gd DTPA动态增强 (6 3.3% ) ,与后两者之间均有统计学差异。结论 Gd BOPTA动态增强MRI对SHCC的检出率和准确性高于MRI平扫 ,对SHCC包膜的显示率明显优于Gd DTPA增强和平扫MRI,延迟像利于提高病变的检出率和定性 。 Objective To compare gadobenate dimeglumine (Gd-BOPTA) enhanced MRI, plain MRI and Gd-DTPA dynamic MRI in diagnosing small hepatocellular carcinoma (SHCC), to further improve the detecting rate and diagnostic accuracy of SHCC. Materials and Methods Twenty-five patients with pathologically proved SHCC underwent MR examination with a 1.5T Signa scanner. The exam included SE T 1WI, FSE T 2WI, Gd-DTPA dynamic enhanced MRI and Gd-BOPTA dynamic enhanced MRI. DCE MRI scanning started when the intravenous infu...
出处 《临床放射学杂志》 CSCD 北大核心 2004年第12期1052-1057,共6页 Journal of Clinical Radiology
基金 卫生部临床学科重点基金项目 (编号 2 0 0 114 2 0 )
关键词 磁共振成像 GD-BOPTA GD-DTPA 小肝癌 Magnetic resonance imaging Gadobenate dimeglumine Small hepatocellular carcinoma
  • 相关文献

参考文献18

  • 1刘剑羽,谢敬霞,姚学会,韩鸿宾,郑卓肇.菲立磁增强MRI在肝脏局灶性病变诊断中的价值[J].临床放射学杂志,2001,20(4):256-258. 被引量:7
  • 2[3]Low RN,Francis IR,Sigeti JS,et al.Abdominal MR imaging: comparison of T2-weighted fast and conventional spin-echo,and contrast-enhanced fast multiplanar spoiled gradient-recalled imaging.Radiology,1993,186:803
  • 3[4]Whiteney WS,Herfken RJ,Jeffrey RB,et al.Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with Gadolinium-enhancement for differentiating hepatic hemangiomas from malignancies at 1.5T.Radiology,1993,189:863
  • 4[5]Fujita T,Ito K,Honjo K,et al.Detection of hepatocellular carcinoma: comparison of T2-weighted breath-hold fast spin-echo sequences and high-resolution dynamic MR imaging with a phased-array body coil.J Magn Reson Imaging,1999,9:274
  • 5严福华,周康荣,吴东,杨军,龚静山,沈继章.快速多层面干扰梯度回波序列动态增强扫描在小肝癌诊断中的价值评估[J].中华肝脏病杂志,2001,9(3):139-141. 被引量:6
  • 6[7]Toft KG,Hustvedt SO,et al.Metabolism and pharmacokinetics of Mn-DPDP in man.Acta Radiologica,1997,38:677
  • 7[8]Hannhn PF and Saini S.Liver-specific MR imaging contrast agents.Radiol Clini Nor Am,1998,36:287
  • 8[9]Kirchin MA,Pirovano GP,Spinazzi A.Gadobenate dimeglumine (Gd-BOPTA): an overview.Invest Radiol,1998,33:798
  • 9[10]Spinazzi A,Lorusso V,Pirovano G,et al.Safety,tolerance,biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.Acad Radiol,1999,6:282
  • 10[11]Kirchin MA,Pirovano G,Venetianer C,et al.Safety assessment of gadobenate dimeglumine (Multihance): extended clinical experience from phase Ⅰ studies to post-marketing surveillance.J Magn Reson Imaging,2001,14:281

二级参考文献14

  • 1[1]Ros PR, Freeny PC, Harms SE,et al. Hepatic MR imaging with Ferum-oxides: A multicenter clinical trial of the safty and efficacy in the detection of focal hepatic lesions. Radiology, 1995, 196:481
  • 2[2]Hagspiel KD, Neidl KF, Eichenberger AC,et al. Detection of liver metastases: Comparison of superparamagnetic iorn oxide-enhanced and unenhanced MR imaging at 1.5T with dynamic CT, intraoperative US, and percutaneous US. Radiology, 1995, 196:471
  • 3[3]Kondo H, Kanematsu M, Hoshi H,et al. Preoperative detection of malignant hepatic tumors: Comparison of combined methods of MR imaging with combined methods of CT. AJR, 2000, 174:947
  • 4[4]Kanematsu M, Hoshi H, Itoh K,et al. Focal hepatic lesion detection: Comparison of four fat-suppressed T2-weighted MR imaging pulse sequences. Radiology, 1999, 211:367
  • 5[5]Nakayama M, Yamashita Y, Mitsuzaki K,et al. Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2 weighted MR imaging. J Magn Reson Imaging, 2000, 11:647
  • 6Wang C, Gordon PB, Hustvedt SO, et al. MR imaging properties and phar-macokinetics of MnDPDP in healthy volunteers. Acta Radiologica, 1997,38:665
  • 7Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonanceimaging of the liver and pancreas. Acta Radiologica, 1998, 39:7
  • 8Rummeuy EJ, Torres CG, Kurdziel JC, et al. MnDPDP for MR imaging of the liver: results of independent image evaluation of the European phase Ⅲstudies. Acta Radiologica, 1997, 38:638
  • 9Jung G, Heindel W, Krahe T, et al. Influence of the hepatobiliary contrastagent mangafodipir trisodium (MnDPDP) on the imaging properties of the abdominal organ. Magn Reson Imaging, 1998, 16(8):925
  • 10Toft KG, Kindberg GM and Skotland T, et al. Mangafodipir trisodium injec-tion, a new contrast medium for magnetic rsonance imaging. In vitro metaboliem and protien binding studies of the active component MnDPDP in human blood. J Pharm Biomed Anal, 1997,15:983

共引文献13

同被引文献155

引证文献12

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部